Search the Newsreel

UBS Adjusts J.M. Smucker Price Target to $142 From $130, Maintains Buy Rating

UBS has increased its price target for J.M. Smucker (SJM) to $142 from $130, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the analyst firm. Other firms like TD Cowen, Jefferies, Deutsche Bank, and JPMorgan have also …

FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival

Rein Therapeutics (NASDAQ: RNTX) announced that its lead candidate, LTI-03, an inhaled peptide for idiopathic pulmonary fibrosis (IPF), has received Fast Track designation from the U.S. FDA. This designation aims to expedite development and review for serious conditions with unmet medical needs. The company …

From Land Securities Group (LSE:LAND) To Renewables Infrastructure Group (LSE:TRIG): What Is Separating Infra and Real Estate Stocks Today?

From Hikma Pharmaceuticals (LSE:HIK) To Spire Healthcare Group (LSE:SPI): What Is Separating Healthcare Stocks Today?

Helios Technologies (HLIO) Just Posted Record Numbers, Can It Keep Climbing

On August 10, Helios Technologies (NASDAQ:HLIO) reported second-quarter results that pushed its turnaround story into a new chapter. Sales hit $232 million, landing at the top end of management's own guidance, while adjusted earnings cleared the high end of the outlook. It marked the …

Arrowhead Pharmaceuticals (ARWR) Advances REDEMPLO Launch, Is The Stock Still Undervalued?

Xinchen China Power Profit Rises Despite Steep Revenue Drop

Archer Aviation (ACHR) Bets Big On Becoming More Than An Air Taxi Company

On August 10, Archer Aviation (NYSE:ACHR) held its second-quarter earnings call and used it to lay out a transformation few investors saw coming. The company announced agreements to acquire three Boeing-owned businesses, Wisk Aero, Insitu and SkyGrid, in exchange for Boeing taking a strategic …

Motor & General Finance Ltd. Revenue Breakdown – NSE:MOTOGENFIN

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright

HC Wainwright has reiterated a "Buy" rating for Zevra Therapeutics (NASDAQ:ZVRA) with a $26 price target, suggesting a significant upside. This positive outlook is echoed by other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $27.14. The company …

Radiopharm advances RAD202 trial to higher dose level By Investing.com

Radiopharm Theranostics has received approval from its Data Safety and Monitoring Committee to increase the dose level of its RAD202 radiotherapeutic to 180mCi in a Phase 1 clinical trial. The trial, named HEAT, is evaluating 177Lu-RAD202 in patients with HER2-positive advanced solid tumors. This …

Is National Health Investors (NHI) Undervalued After Its Earnings And Dividend Update?

National Health Investors (NHI) recently reported higher Q2 2026 revenue and net income, along with a small dividend increase to $0.94 per share. While its 3-year shareholder return is strong, recent performance has been mixed. The company is considered 14.6% undervalued with an implied …

Why Is American Healthcare REIT (AHR) Back On Investors’ Radar?

American Healthcare REIT (AHR) has garnered renewed investor interest following strong Q2 results, increased revenue and net income, and raised full-year earnings guidance for 2026. Despite a recent share price pullback, the stock has delivered significant year-to-date and one-year returns. While some analyses suggest …

Cheniere Energy Partners (CQP), Why Is Its Latest Update Drawing Attention?

Cheniere Energy Partners (CQP) reported strong Q2 and H1 2026 results, showing higher profitability year-over-year and a significant year-to-date share price return of 27.26%. While the company's P/E ratio of 12.5x appears undervalued compared to market and peer benchmarks, a discounted cash flow (DCF) …

TherapeuticsMD, Inc. Revenue Breakdown – NASDAQ:TXMD

This article provides a revenue breakdown for TherapeuticsMD, Inc. (NASDAQ: TXMD), highlighting that the greatest contribution to its revenue came from the United States, accounting for $1.79 million USD last year and $1.12 million USD the year prior. The data is presented through TradingView, …

Travelers Companies (TRV) Q2 Profit Rebound Puts Its Valuation Back In Focus

Travelers Companies (TRV) reported a strong Q2 2026 profit rebound driven by lower catastrophe losses and higher investment income, leading to an 8.2% share price increase and a 39% one-year total shareholder return. Despite this, a common valuation model suggests TRV is about 4% …

Northern Trust expands First Sentier mandate for $14B Irish fund structure

* Northern Trust Corporation (NTRS [https://seekingalpha.com/symbol/NTRS]) expanded [https://seekingalpha.com/pr/20624978-northern-trust-expands-relationship-with-first-sentier-group-to-support-irish-fund-structure] its relationship with First Sentier Group after being appointed fund administrator and depositary for the asset manager’s $14B Irish fund structure. * Under the mandate, Northern Trust Corporation (NTRS [https://seekingalpha.com/symbol/NTRS]) will provide custody, depositary, fund accounting, …

Henderson Investment Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Cardinal Health CIO Greene sells $2.75m in stock

Michelle D. Greene, CIO of Cardinal Health Inc. (NASDAQ:CAH), sold 11,650 shares for $2.75 million on August 18, 2026, with transactions ranging from $234.07 to $237.32 per share. This sale follows a strong 55% return for Cardinal Health shares over the past year. The …

Goosehead Insurance And Two More Stocks Estimated To Be Trading Below Intrinsic Value

Helios (HLIO) Q2 2026 Results: Profit Per Share Clears Its Benchmark; Closing Reaction: Shares Move 4.09% Down at the Close - Diluted EPS Report

Helios (HLIO) Q2 2026 Results: Profit Per Share Clears Its Benchmark; Closing Reaction

Black (BDTX) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Share Response: The Share Price Adds 6.31% in Latest Trading - Profit Growth Outlook

Las acciones de Sherwin Williams (SHW) parecen sobrevaloradas y con un potencial alcista limitado

Die Aktie von Sherwin Williams (SHW) erscheint überbewertet und bietet nur begrenztes Aufwärtspotenzial

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response

Universal Health Services (UHS) Q2 Earnings and Revenues Top Estimates

Enterprise value to revenue forward of Hightide Therapeutics Inc – HKEX:2511

Paychex stock holds above $120 as revenue growth accelerates

Paychex Inc. (US7043261079) stock is trading above $120 after reporting strong double-digit revenue and earnings growth for the fiscal third quarter ended February 28, 2026. The company's total revenue increased by 20% to $1.8 billion, driven by high demand for its human capital management …

Why Is CIFR Stock Rising Despite Q1 Earnings Miss?

UBS raises Iovance Biotherapeutics stock price target on revenue beat

Lockheed Martin (LMT) Completes First Japan ASEV In Indo Pacific Defense Milestone

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Lockheed Martin (NYSE:LMT) has completed the first fully integrated Aegis System Equipped Vessel for Japan, marking a new milestone for Indo Pacific missile …

Toll Brothers (TOL) Could Be 7% Undervalued Following Earnings Beat And Reaffirmed Guidance

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Toll Brothers (TOL) stock came into focus after the builder reported third quarter results that topped analyst forecasts for revenue and earnings per …

The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920

PTC Therapeutics recently discussed the positive regulatory progress of ST-920, supported by Phase 1/2 STAAR data showing significant renal benefits and a favorable safety profile. This development could reshape the company's investment narrative and pipeline, diversifying beyond its current commercial base. While PTC Therapeutics …

131,800 Shares in Healthcare Services Group, Inc. $HCSG Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC recently acquired a new stake of 131,800 shares in Healthcare Services Group, Inc. (NASDAQ:HCSG), valued at approximately $3.24 million. Other institutional investors also adjusted their positions in the company, which saw its stock rise by 4.5%. Healthcare Services Group reported …

Fractyl Health to Host Virtual Commercial Strategy Day on

Fractyl Health, Inc. will host a virtual Commercial Strategy Day on September 1, 2026, to discuss the commercial opportunity and go-to-market strategy for Revita, a procedural therapy for post-GLP-1 weight maintenance. This event follows positive one-year data from the REMAIN-1 Midpoint Cohort, which demonstrated …